José C Quílez Conde, Inmaculada Parra Ribes, Josep Perelló-Capo, Paloma Lobo Abascal, Ignacio Cristóbal García, Mercedes Andeyro García, José Gutiérrez Alés, Mercedes Herrero Conde, Joan Rius Tarruella, Belén Espinós Lafuente
{"title":"西班牙用于避孕的 52 毫克左炔诺孕酮释放宫内节育器 (LNG-IUS) 与其他长效可逆避孕药的成本效益分析。","authors":"José C Quílez Conde, Inmaculada Parra Ribes, Josep Perelló-Capo, Paloma Lobo Abascal, Ignacio Cristóbal García, Mercedes Andeyro García, José Gutiérrez Alés, Mercedes Herrero Conde, Joan Rius Tarruella, Belén Espinós Lafuente","doi":"10.1080/13625187.2024.2369843","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Condoms and combined oral contraceptive pills are widely used in Spain with high failure rates. Long-Acting Reversible Contraceptive (LARC) methods offer better efficacy and adherence and reduce unintended pregnancies (UP) compared with short-acting reversible contraceptive (SARC) methods.</p><p><strong>Objective: </strong>To assess the cost-effectiveness of LNG-IUS 52 mg (Mirena<sup>®</sup>) versus other LARC for contraception in Spain.</p><p><strong>Materials and methods: </strong>A Markov model with annual cycles and an eight-year time horizon was developed from the Spanish national healthcare system (NHS) perspective, considering costs for contraceptive method acquisition, health care resources (HCR) and UP. Effectiveness was based on failure and discontinuation rates. Sensitivity analyses were performed to test the model's robustness.</p><p><strong>Results: </strong>LNG-IUS 52 mg (Mirena<sup>®</sup>) resulted in lower costs and fewer UP versus LNG-IUS 13.5 mg (Jaydess<sup>®</sup>), Implant (Implanon<sup>®</sup>) and Copper IUD. LNG-IUS 52 mg (Levosert<sup>®</sup>) prevented the same UP events at a higher cost. LNG-IUS 19.5 mg (Kyleena<sup>®</sup>) was the most effective option, due to a lower discontinuation rate.</p><p><strong>Conclusions: </strong>LNG-IUS 52 mg (Mirena<sup>®</sup>) is the least costly LARC, driven by lower acquisition costs and reduced HCR utilisation. Increasing LNG-IUS 52 mg (Mirena<sup>®</sup>) uptake in contraception could generate further cost savings for the Spanish NHS and reduce economic burden of UP.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain.\",\"authors\":\"José C Quílez Conde, Inmaculada Parra Ribes, Josep Perelló-Capo, Paloma Lobo Abascal, Ignacio Cristóbal García, Mercedes Andeyro García, José Gutiérrez Alés, Mercedes Herrero Conde, Joan Rius Tarruella, Belén Espinós Lafuente\",\"doi\":\"10.1080/13625187.2024.2369843\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Condoms and combined oral contraceptive pills are widely used in Spain with high failure rates. Long-Acting Reversible Contraceptive (LARC) methods offer better efficacy and adherence and reduce unintended pregnancies (UP) compared with short-acting reversible contraceptive (SARC) methods.</p><p><strong>Objective: </strong>To assess the cost-effectiveness of LNG-IUS 52 mg (Mirena<sup>®</sup>) versus other LARC for contraception in Spain.</p><p><strong>Materials and methods: </strong>A Markov model with annual cycles and an eight-year time horizon was developed from the Spanish national healthcare system (NHS) perspective, considering costs for contraceptive method acquisition, health care resources (HCR) and UP. Effectiveness was based on failure and discontinuation rates. Sensitivity analyses were performed to test the model's robustness.</p><p><strong>Results: </strong>LNG-IUS 52 mg (Mirena<sup>®</sup>) resulted in lower costs and fewer UP versus LNG-IUS 13.5 mg (Jaydess<sup>®</sup>), Implant (Implanon<sup>®</sup>) and Copper IUD. LNG-IUS 52 mg (Levosert<sup>®</sup>) prevented the same UP events at a higher cost. LNG-IUS 19.5 mg (Kyleena<sup>®</sup>) was the most effective option, due to a lower discontinuation rate.</p><p><strong>Conclusions: </strong>LNG-IUS 52 mg (Mirena<sup>®</sup>) is the least costly LARC, driven by lower acquisition costs and reduced HCR utilisation. Increasing LNG-IUS 52 mg (Mirena<sup>®</sup>) uptake in contraception could generate further cost savings for the Spanish NHS and reduce economic burden of UP.</p>\",\"PeriodicalId\":1,\"journal\":{\"name\":\"Accounts of Chemical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":16.4000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Accounts of Chemical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13625187.2024.2369843\",\"RegionNum\":1,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13625187.2024.2369843","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain.
Introduction: Condoms and combined oral contraceptive pills are widely used in Spain with high failure rates. Long-Acting Reversible Contraceptive (LARC) methods offer better efficacy and adherence and reduce unintended pregnancies (UP) compared with short-acting reversible contraceptive (SARC) methods.
Objective: To assess the cost-effectiveness of LNG-IUS 52 mg (Mirena®) versus other LARC for contraception in Spain.
Materials and methods: A Markov model with annual cycles and an eight-year time horizon was developed from the Spanish national healthcare system (NHS) perspective, considering costs for contraceptive method acquisition, health care resources (HCR) and UP. Effectiveness was based on failure and discontinuation rates. Sensitivity analyses were performed to test the model's robustness.
Results: LNG-IUS 52 mg (Mirena®) resulted in lower costs and fewer UP versus LNG-IUS 13.5 mg (Jaydess®), Implant (Implanon®) and Copper IUD. LNG-IUS 52 mg (Levosert®) prevented the same UP events at a higher cost. LNG-IUS 19.5 mg (Kyleena®) was the most effective option, due to a lower discontinuation rate.
Conclusions: LNG-IUS 52 mg (Mirena®) is the least costly LARC, driven by lower acquisition costs and reduced HCR utilisation. Increasing LNG-IUS 52 mg (Mirena®) uptake in contraception could generate further cost savings for the Spanish NHS and reduce economic burden of UP.
期刊介绍：
Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance.
Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
